Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.47 |
| ▸ | HTR3B | O95264 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.47 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.47 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.47 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20687962 | 0.81 | PARP1 (0.49) | L3MBTL1PARP1CNR2PDE10ACYP1A2 | |
| SCHEMBL22136195 | 0.81 | PARP1 (0.58) | L3MBTL1PARP1CNR2PDE10ACYP1A2 | |
| SCHEMBL23967004 | 0.80 | PARP1 (0.48) | L3MBTL1PARP1HTR3EHTR3BHTR3A | |
| SCHEMBL26685500 | 0.80 | CNR2 (0.49) | L3MBTL1PARP1HTR3EHTR3BHTR3A | |
| SCHEMBL19994372 | 0.80 | PARP1 (0.48) | L3MBTL1PARP1ALOX5CNR2PDE10A | |
| SCHEMBL29464219 | 0.80 | PARP1 (0.48) | L3MBTL1PARP1ALOX5CNR2PDE10A | |
| SCHEMBL20688065 | 0.80 | PARP1 (0.48) | L3MBTL1PARP1ADORA2AADORA1CNR2 | |
| SCHEMBL20889900 | 0.80 | PARP1 (0.45) | L3MBTL1PARP1CNR2PDE10ACYP1A2 | |
| SCHEMBL21227327 | 0.77 | IDH1 (0.47) | L3MBTL1PARP1CNR2PDE10AIDH1 | |
| SCHEMBL7806232 | 0.77 | L3MBTL1 (0.50) | RECQLL3MBTL1ADORA2AADORA1PDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107393-A1 | TRICYCLIC COMPOUNDS | SCHRÖDINGER, INC. (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3538525-B1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-22 | — | — | EP | disclosed |
| WO-2021262836-A1 | 3.ALPHA.-HYDROXY, 17.BETA.-C(O)-N-ARYL SUBSTITUTED NEUROACTIVE STEROIDS AND COMPOSITIONS THEREOF | SAGE THERAPEUTICS, INC. (US) | 2021-12-30 | — | — | WO | disclosed |
| EP-3538519-B1 | INDAZOLE DERIVATIVES AS ALPHA V INTEGRIN ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-04-06 | — | — | US | disclosed |
| US-10954253-B2 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | Shijiazhuang Sagacity New Drug Development Co., Ltd. (CN) | 2021-03-23 | — | — | US | disclosed |
| EP-3538528-B1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-09-05 | — | — | US | disclosed |
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2019-08-29 | — | — | US | disclosed |
| WO-2019074979-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | GIRAFPHARMA, LLC (US) | 2019-04-18 | — | — | WO | disclosed |
| WO-2018089357-A1 | INDAZOLE DERIVATIVES AS αV INTEGRIN ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089353-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018089360-A1 | PYRROLE AMIDES AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190263808-A1 | 3-SUBSTITUTED PROPIONIC ACIDS AS ALPHA V INTEGRIN INHIBITORS | ITGAV, ITGB3, ITGB1 | RECQL 4859/4885L3MBTL1 3091/4885PARP1 1286/4885 |
| US-20190270741-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | RECQL 4785/4885L3MBTL1 4413/4885PARP1 2432/4885 |
| US-10954253-B2 | 1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one derivative as Wee1 inhibitor | WEE1, WEE2, CCNE1 | RECQL 1491/4885L3MBTL1 2840/4885PARP1 358/4885 |
| US-10968219-B2 | 3-substituted propionic acids as αV integrin inhibitors | ITGB3, ITGB1, ITGAV | RECQL 4872/4885L3MBTL1 3330/4885PARP1 1525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.